North America Mycoplasma Testing Market Size & Outlook
North America mycoplasma testing market, 2018-2030 (US$M)
Related Markets
North America mycoplasma testing market highlights
- The North America mycoplasma testing market generated a revenue of USD 368.6 million in 2023.
- The market is expected to grow at a CAGR of 13.3% from 2024 to 2030.
- In terms of segment, kits & reagents was the largest revenue generating product in 2023.
- Services is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 368.6 million |
| Market revenue in 2030 | USD 880.7 million |
| Growth rate | 13.3% (CAGR from 2023 to 2030) |
| Largest segment | Kits & reagents |
| Fastest growing segment | Services |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Instruments, Kits & Reagents, Services |
| Key market players worldwide | Thermo Fisher Scientific Inc, Lonza Group Ltd, Merck KGaA, Charles River Laboratories International Inc, Asahi Kasei Corp, Sartorius AG, Eurofins Scientific SE, PromoCell GmbH, ATCC, InvivoGen |
Other key industry trends
- In terms of revenue, North America region accounted for 39.0% of the global mycoplasma testing market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 528.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Mycoplasma Testing Market Scope
Mycoplasma Testing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America mycoplasma testing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mycoplasma testing market will help companies and investors design strategic landscapes.
Kits & reagents was the largest segment with a revenue share of 56.21% in 2023. Horizon Databook has segmented the North America mycoplasma testing market based on instruments, kits & reagents, services covering the revenue growth of each sub-segment from 2018 to 2030.
Mycoplasma testing has seen a significant rise in demand in the region due to its critical role in ensuring the safety & quality of biological products and research. Mycoplasmas, a group of bacteria lacking cell walls, can contaminate cell cultures and biological materials, leading to erroneous research results and compromised product integrity.
The biopharmaceutical and biotechnology industries are particularly impacted, as mycoplasma contamination can alter cell behavior and compromise the efficacy of biologics & vaccines. Regulatory agencies like the FDA have stringent guidelines for mycoplasma testing, further driving its necessity. Advances in detection methods, such as PCR and ELISA, have improved the accuracy and speed of testing, making it more accessible and essential.
With the growing emphasis on precision medicine and biologics, the demand for reliable mycoplasma testing is expected to continue its upward trend, ensuring the production of safe and effective biomedical products.
Reasons to subscribe to North America mycoplasma testing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America mycoplasma testing market databook
-
Our clientele includes a mix of mycoplasma testing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America mycoplasma testing market , including forecasts for subscribers. This continent databook contains high-level insights into North America mycoplasma testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America mycoplasma testing market size, by country, 2018-2030 (US$M)
North America Mycoplasma Testing Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
